Average of confirmed sales; the main valuation baseline.
Lowest active listing; an asking price, not a completed sale.
Reference-price movement; low volume can make it unstable.
More sales reduce the impact of individual transactions.
Sales answer “what is it worth”; listings answer “what does an available copy cost”.
SALES / VALUECompleted eBay sales; useful support, especially for the global market.
Transaction-based price; use it as the valuation baseline.
Transaction-based price; use it as the valuation baseline.
Seller asking prices. They show availability but do not prove demand.
| DATE | SOURCE | Price | Change |
|---|---|---|---|
| 2026-11-07 | Sold | €82.24 | -3.1% |
| 2026-11-07 | List | €79.19 | +0.3% |
| 2026-11-07 | TCG | $55.75 | — |
| 2026-11-06 | Sold | €84.87 | — |
| 2026-11-06 | TCG | $55.75 | -0.9% |
| 2026-11-06 | EB | $45.00 | -13.5% |
| 2026-11-05 | Sold | €84.87 | -3.8% |
| 2026-11-05 | List | €78.95 | -0.6% |
| 2026-11-05 | TCG | $56.25 | -0.2% |
| 2026-11-04 | Sold | €88.20 | +6.2% |
| 2026-11-04 | TCG | $56.35 | -0.7% |
| 2026-11-04 | EB | $52.00 | -1.5% |
| 2026-11-03 | Sold | €83.03 | — |
| 2026-11-03 | TCG | $56.72 | -1.5% |
SV: Scarlet & Violet 151 / #201/165/Holofoil
Spain: lowest · Italy: below average · EU average €79.30Choose a region above to inspect its prices and history.
DETAILED PRICES · Price History
| Condition/Grade | Price | LOW | HIGH | 7D CHG | Volume | Spark |
|---|---|---|---|---|---|---|
NMRAW | $49.59 | $45.00 | $45.00 | +8.2% | >5 | |
LPRAW | $51.21 | $51.21 | $51.21 | +8.2% | >5 | |
AggregatedRAW | €82.24 | €36.00 | €246.00 | +8.2% | >5 | |
DMGRAW | $36.99 | $34.00 | $39.99 | +8.2% | >5 | |
MPRAW | $59.64 | $59.64 | $59.64 | +8.2% | >5 | |
HEAVILY PLAYEDRAW | $57.50 | $57.50 | $57.50 | +8.2% | >5 | |
MINTRAW | €82.24 | €36.00 | €246.00 | +8.2% | >5 |
Explore Alakazam ex #201/165, Holofoil from SV: Scarlet & Violet 151, with 2812 price records for the US market. Prices above are labeled by source, currency and condition. Asking prices and recorded sales are different measures, not interchangeable valuations.